Battle against the renin-angiotensin system: Help from an unexpected party

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1110-1112

  Müller, Dominik ^a,c   Müller, Dominik N ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CALCITRIOL; CALCIUM; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PARICALCITOL; PHOSPHORUS; PLACEBO; RENIN; STREPTOZOCIN; VITAMIN D DERIVATIVE;

DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; OSSIFICATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ERGOCALCIFEROLS; LOSARTAN; MICE; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 65349149637     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn764     Document Type: Short Survey

References (22)

1. Smolders J, Damoiseaux J,Menheere P et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7-17
2. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20: 713-719
3. Lind L, Wengle B, Wide L et al. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidiol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens 1989; 2: 20- 25
4. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16180- 16815
5. Kimura Y, Kawamura M, Owada M et al. Effectiveness of 1,25 dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med 1999; 38: 31-35
6. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81
7. Li YC, Kong J,WeiMet al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest2002; 110: 229-238
8. Zhou C, Lu F, Cao K et al. Calcium-independent and 1,25(OH)2D3- dependent regulation of the renin-angiotensin system in 1ahydroxylase knockout mice. Kidney Int 2008; 74: 170-179
9. Zhang Z, Zhang Y, Ning G et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 41: 15896-15901
10. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
11. Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53-57
12. Eijkelkamp WA, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol 2007; 18: 1540- 1546
13. Luetscher JA, Kraemer FB, Wilson DM et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417
14. Wilson, DM, Luetscher, JA. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1101-1106
15. Nguyen G, Delarue F, Burckl'e C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427
16. Feldt S, Batenburg WW, Mazak I et al. Prorenin and renininduced ERK 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2007; 51: 682- 688
17. Ichihara A, Suzuki F, Nakagawa T et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950- 1961.
18. Navarro-Gonz'alez JF, Mora-Fern'andez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008; 19: 433- 442
19. Gregori S, Giarratana N, Smiroldo S et al. A 1alpha,25- dihydroxyvitamin D (3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367- 1374
20. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 23: 7861- 7864
21. Cantorna MT, Hayes CE, DeLuca HF 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128: 68-72
22. Szanya V, Ermann J, Taylor C et al. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002; 169: 2461-2465